Current Report Filing (8-k)
22 7월 2022 - 5:07AM
Edgar (US Regulatory)
0001427570
false
0001427570
2022-07-15
2022-07-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 15, 2022
RESHAPE LIFESCIENCES
INC.
(Exact name of registrant as specified in its charter)
Delaware |
1-37897 |
26-1828101 |
(State or other jurisdiction of
incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
|
|
|
1001 Calle Amanecer
San Clemente, CA |
92673 |
(Address of principal executive offices) |
(Zip Code) |
|
|
|
|
(949) 429-6680
(Registrant’s
telephone number, including area code)
Not applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| | |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| | |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title
of Class |
Trading
Symbol |
Name
of Exchange on which Registered |
Common stock, $0.001 par value per share |
RSLS |
The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 4.01 | Changes in Registrant’s Certifying
Accountant. |
On
July 15, 2022, the Audit Committee of the Board of Directors of ReShape Lifesciences Inc. (the “Company”) appointed RSM
US LLP (“RSM”) as the Company’s independent registered public accounting firm. During the fiscal years ended December 31,
2021 and 2020, and during the subsequent interim periods through RSM’s appointment, neither the Company nor anyone on its behalf
consulted with RSM regarding the application of accounting principles to a specified transaction, either completed or proposed, or the
type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice
was provided to the Company that RSM concluded was an important factor considered by the Company in reaching a decision as to any accounting,
auditing, or financial reporting issue, any matter that was the subject of a “disagreement” with its former auditors or a
“reportable event,” as those terms are defined in Item 304 of Regulation S-K.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
RESHAPE LIFESCIENCES INC. |
|
|
|
|
By: |
/s/ Tom Stankovich |
|
|
Tom Stankovich |
|
|
Chief Financial Officer |
Dated: July 21, 2022
Obalon Therapeutics (NASDAQ:OBLN)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Obalon Therapeutics (NASDAQ:OBLN)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Obalon Therapeutics Inc (나스닥)의 실시간 뉴스: 최근 기사 0
More Reshape Lifesciences Inc. News Articles